- The FDA has granted Fast Track Designation to Aquestive Therapeutics Inc's (NASDAQ:AQST) AQST-109 for allergic reactions.
- AQST-109 is an orally delivered epinephrine-based product candidate for the emergency treatment of allergic reactions, including anaphylaxis.
- Aquestive recently announced results from Part 1 of its EPIPHAST study in healthy adult subjects comparing AQST-109 to intramuscular injection of epinephrine.
- The Company commenced Part 2 of the study, which compares AQST-109 to intramuscular injection of epinephrine 0.3mg, which is the dosage of epinephrine auto-injectors.
- Aquestive expects to report topline results for the full EPIPHAST study in 1H of 2022.
- Related: Aquestive Highlights Early Data From Allergy Treatment Candidate AQST-109 Study.
- Aquestive opened an Investigational New Drug Application (IND) with the FDA in February 2022. The Company anticipates conducting an end of Phase 2 meeting with the FDA during 2H of 2022.
- AQST-109 is a polymer matrix-based epinephrine prodrug administered as a sublingual film applied under the tongue for the rapid delivery of epinephrine.
- The product is similar to a postage stamp, weighs less than an ounce, and begins to dissolve on contact. No water or swallowing is required for administration.
- Price Action: AQST shares are up 4.60% at $2.73 during the market session on the last check Thursday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Aquestive's AQST-109 Receives Fast Track Tag For Allergic Reactions
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks